New shot aims to stop mouth lesions before they become cancer

NCT ID NCT07620496

Not yet recruiting Disease control Sponsor: Providence Health & Services Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a drug called CAN1012, which is injected directly into pre-cancerous mouth lesions. The goal is to see if it is safe and can activate the immune system to fight the abnormal cells. The study involves 36 adults with oral epithelial dysplasia who will receive the injection before their planned surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAN1012 (a drug injected into the lesion to activate the immune system)
What this could lead to: If successful, this could point toward a treatment that prevents oral dysplasia from turning into cancer, reducing the need for surgery.
What could go wrong: This is a very early, small phase 1 trial focused on safety, not effectiveness. The drug may cause side effects or fail to work in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates